Indirect comparisons of oral fingolimod versus natalizumab and cladribine for the treatment of relapsing-remitting multiple sclerosis based on data from FREEDOMS, AFFIRM and CLARITY

被引：0
|
作者：
Nixon, R.
Eckert, B.
Cutter, G.
Mercier, F.
Francis, G.
Kappos, L.
机构：
[1] Novartis Pharma AG, Basel, Switzerland
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Univ Alabama Birmingham, Birmingham, AL USA
[4] Novartis Inst Biomed Res Inc, Cambridge, MA USA
[5] Univ Basel Hosp, CH-4031 Basel, Switzerland
来源：
JOURNAL OF NEUROLOGY | 2012年 / 259卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S68 / S68
页数：1
相关论文
共 50 条
  • [41] Comparison of the effectiveness of ocrelizumab vs interferons, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis
    Roos, I.
    Sharmin, S.
    Ozakbas, S.
    Horakova, D.
    Havrdova, E. K.
    Boz, C.
    Alroughani, R.
    Patti, F.
    Terzi, M.
    Lechner-Scott, J.
    Izquierdo, G.
    Eichau, S.
    Grammond, P.
    Buzzard, K.
    Skibina, O.
    Prat, A.
    Girard, M.
    Duquette, P.
    Soysal, A.
    Grand'Maison, F.
    Kuhle, J.
    van der Walt, A.
    Butzkueven, H.
    Turkoglu, R.
    Butler, E.
    Laureys, G.
    van Hijfte, L.
    Shaygannejad, V.
    Yamout, B.
    Khoury, S.
    Prevost, J.
    Sidhom, Y.
    Gouider, R.
    Cartechini, E.
    Sanchez-Menoyo, J. L.
    Sa, M. Jose
    Macdonell, R.
    van Pesch, V.
    Ramo-Tello, C.
    McCombe, P.
    Willekens, B.
    Spitaleri, D.
    Ampapa, R.
    Al-Asmi, A.
    Slee, M.
    Besora, S.
    Malpas, C.
    Kalincik, T.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 778 - 780
  • [42] Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing-Remitting Multiple Sclerosis
    Grahl, S.
    Bussas, M.
    Wiestler, B.
    Eichinger, P.
    Gaser, C.
    Kirschke, J.
    Zimmer, C.
    Berthele, A.
    Hemmer, B.
    Muehlau, M.
    NEUROTHERAPEUTICS, 2021, 18 (04) : 2589 - 2597
  • [43] Real world comparative effectiveness data of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: results from a systematic literature review
    Lang, S.
    Wolff, R.
    Annovazzi, P.
    Baroncini, D.
    Kalincik, T.
    Koch-Henriksen, N.
    Laplaud, D-A.
    Acosta, C.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 610 - 611
  • [44] A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in Chile
    Espinoza, Manuel Antonio
    Rojas, Ruben
    Zaupa, Alessandro
    Balmaceda, Carlos
    PHARMACOECONOMICS-OPEN, 2021, 5 (04) : 635 - 647
  • [45] A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in Chile
    Manuel Antonio Espinoza
    Rubén Rojas
    Alessandro Zaupa
    Carlos Balmaceda
    PharmacoEconomics - Open, 2021, 5 : 635 - 647
  • [46] Fingolimod for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia
    Algahtani, Hussein
    Shirah, Bader
    Al Malik, Yaser
    Meftah, Ibraheem
    CLINICAL NEUROPHARMACOLOGY, 2020, 43 (02) : 35 - 38
  • [47] Switching from natalizumab to ocrelizumab in patients with relapsing-remitting multiple sclerosis
    Van Lierop, Z.
    Toorop, A.
    Willemse, E.
    Strijbis, E.
    Kalkers, N.
    Moraal, B.
    Barkhof, F.
    Teunissen, C.
    Killestein, J.
    Van Kempen, Z.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 310 - 311
  • [48] Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings
    Rinaldi, F.
    Seppi, D.
    Calabrese, M.
    Perini, P.
    Gallo, P.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (11) : 1640 - 1643
  • [49] Comparative effectiveness of natalizumab and fingolimod in subgroups of patients with relapsing-remitting multiple sclerosis from three international cohorts
    Sharmin, Sifat
    Lefort, Mathilde
    Andersen, Johanna Balslev
    Leray, Emmanuelle
    Horakova, Dana
    Havrdova, Eva
    Alroughani, Raed
    Ayuso, Guillermo Izquierdo
    Ozakbas, Serkan
    Patti, Francesco
    Onofrj, Marco
    Lugaresi, Alessandra
    Terzi, Murat
    Grammond, Pierre
    Grand'Maison, Francois
    Yamout, Bassem
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Boz, Cavit
    Trojano, Maria
    McCombe, Pamela
    Slee, Mark
    Lechner-Scott, Jeannette
    Turkoglu, Recai
    Sola, Patrizia
    Ferraro, Diana
    Granella, Franco
    Prevost, Julie
    Maimone, Davide
    Skibina, Olga
    Buzzard, Katherine
    Van der Walt, Anneke
    Van Wijmeersch, Bart
    Csepany, Tunde
    Spitaleri, Daniele Litterio A.
    Vucic, Ostoja
    Casey, Romain
    Debouverie, Marc
    Edan, Gilles
    Ciron, Jonathan
    Ruet, Aurelie
    De Seze, Jerome
    Maillart, Elisabeth
    Zephir, Helene
    Labauge, Pierre
    Defer, Gilles
    Lebrun-Frenay, Christine
    Moreau, Thibault
    Berger, Eric
    NEUROLOGY, 2021, 96 (15)
  • [50] Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM
    Voloshyna, N.
    Havrdova, E.
    Hutchinson, M.
    Nehrych, T.
    You, X.
    Belachew, S.
    Hotermans, C.
    Paes, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 (03) : 570 - 577
12345